Semaglutide use linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients
Background
The co-occurrence of bipolar disorder, diabetes, and obesity is common, suggesting potential shared pathophysiological mechanisms. Current pharmacotherapies for bipolar disorder have seen limited innovation, leaving a gap in managing psychiatric stability, especially in patients with metabolic comorbidities. Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are established treatments for diabetes and obesity, but their potential impact on psychiatric outcomes in conditions like bipolar disorder remains largely unexplored. This study aimed to investigate whether GLP-1RA use could influence relapse indicators in this vulnerable patient population.
Study Design
This nationwide cohort study utilized data from the National Swedish Registers, including 14,694 individuals diagnosed with bipolar disorder who were also prescribed any antidiabetic medication between 2009 and 2024. Of these, 5200 individuals used GLP-1RAs. The researchers employed a rigorous within-individual design to minimize confounding, comparing GLP-1RA use (individually and as a group) against periods of non-use of GLP-1RAs within the same individual, and also against other second-line antidiabetic medications. The primary outcome measured was psychiatric hospitalization for any reason, with secondary outcomes including psychiatric hospitalization due to bipolar disorder relapse and sick leave for psychiatric reasons. Statistical analysis involved within-individual stratified Cox models to calculate adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs).
Results
Among the 14,694 individuals studied, semaglutide use was significantly associated with a 21% (aHR 0.79, 95% CI 0.69-0.91) lower risk of psychiatric hospitalization compared to periods when the same individual was not using GLP-1RAs. This finding highlights a substantial protective effect on overall psychiatric stability. Furthermore, semaglutide was also linked to a 17% (aHR 0.83, 95% CI 0.69-0.99) lower risk of relapse specifically related to bipolar disorder. In contrast, other GLP-1RAs like liraglutide and dulaglutide did not show a statistically significant association with a reduced hospitalization risk in this cohort. Absences from work due to sick leave for psychiatric reasons were not significantly impacted by the specific antidiabetic medications examined in this study. This suggests the benefit might be specific to certain GLP-1RAs or their particular pharmacological profiles.
Semaglutide use was associated with a 21% lower risk of psychiatric hospitalization in individuals with bipolar disorder and metabolic comorbidities.
Key Findings
- Semaglutide use reduced overall psychiatric hospitalization risk by 21% (aHR 0.79, 95% CI 0.69-0.91).
- Semaglutide use lowered the risk of bipolar disorder relapse by 17% (aHR 0.83, 95% CI 0.69-0.99).
- Liraglutide and dulaglutide were not significantly associated with reduced hospitalization risk.
- No significant association was found between antidiabetic medications and sick leave due to psychiatric reasons.
Why It Matters
This study provides compelling evidence that semaglutide may offer a novel adjunctive therapy for improving psychiatric stability in patients with bipolar disorder who also have diabetes and/or obesity. For clinicians, this suggests a potential dual benefit, addressing both metabolic and psychiatric health with a single agent, which could simplify treatment regimens and improve patient outcomes. While not a direct protocol, this finding opens avenues for exploring GLP-1RAs, particularly semaglutide, in integrated care models for neuropsychiatric conditions. Further research is needed to understand the underlying mechanisms, such as potential effects on neuroinflammation or neuroplasticity, and to establish specific dosing protocols for psychiatric indications. This could eventually lead to new guidelines for managing complex patients with co-occurring metabolic and mental health issues.
semaglutide
bipolar-disorder
diabetes
obesity
glp-1ra
psychiatric-hospitalization